---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-072312"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:58:40.010228+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Helix retains ~$120M trust (60%+) after redemptions; PIPE adds ~$261M for BBOT deal

## Summary
- Retained ~$120M in trust (~60%+ of original) after redemptions; 2nd lowest biotech de-SPAC redemption rate since 2022.
- Total expected gross proceeds ~$382M including ~$261M from PIPE led by Cormorant Asset Management and other investors.
- Business combination with BridgeBio Oncology Therapeutics (BBOT) expected to close expeditiously, subject to conditions.
- Redemption request deadline was July 31, 2025; the low redemption rate signals shareholder support for the deal.

## SEC filing metadata
- accession: 0001213900-25-072312
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025072312/0001213900-25-072312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025072312/ea0251994-8k_helix2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-072312
- JSON: https://secwatch.observer/filing/0001213900-25-072312.json
- Plain text: https://secwatch.observer/filing/0001213900-25-072312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.